Spray Based Psilocybin Therapy: Psilocybin Therapy

Biopharmaceutical firm Madrigal Mental Care has announced a new innovative nanotechnology that allows nasal spray psilocybin therapy to provide more thorough and detailed treatment for post-traumatic stress disorder (PTSD).

Psilocybin, the active ingredient in psychedelic hallucinogenic mushrooms, has long shown promise as a potential treatment for PTSD, but dosage control and safety oversight have been an ongoing challenge. This is exactly what Madrigal nasal spray technology is designed to overcome. The system, invented by Professor Amnon Sintov of Ben Gurion University of the Negev, uses biodegradable nanoparticles to deliver psilocybin in controlled doses in a targeted and rapid manner.

While preclinical and human clinical trials need to be done to help bring the treatment to market, the advent of spray-based psilocybin therapy is a promising development for the nascent psychedelic therapy market.

Image Credit: Madrigal Mental Care